Context: Despite a position as the first-line pharmacotherapy in type 2 diabetes, the glucoselowering mechanisms of metformin remain to be fully clarified. Gut-derived modes of action, including suppression of bile acid reabsorption and a resulting increase in glucagon-like peptide-1 (GLP-1) secretion, have been proposed.
M
etformin is the recommended first-line pharmacotherapy of type 2 diabetes and continues to be the most widely used glucose-lowering drug in these patients (1) . The glucose-lowering mechanisms of metformin have not been fully clarified despite the fact that the drug class of biguanides was introduced .50 years ago (2) . Suppression of endogenous hepatic glucose production alongside increased peripheral insulin sensitivity and glucose uptake in skeletal muscle and adipose tissue are traditionally accepted as glucose-lowering modes of action of metformin (3) . However, a range of potential gut-derived glucose-lowering mechanisms of metformin has been proposed during recent years. As recently reviewed by McCreight et al. (4) , these mechanisms include increased intestinal glucose utilization (5), adenosine monophosphate-activated protein kinasemediated activation of vagal afferents with subsequent reduction of hepatic glucose production (6) , modification of the enterohepatic bile acid circulation (7), increased glucagon-like peptide-1 (GLP-1) secretion from intestinal L cells (8) (9) (10) (11) , and/or changes in gut microbiota composition (12) . The focus of the current study was the potential GLP-1-stimulatory effect of single-dose metformin itself and metformin's possible potentiation of bile acid-mediated GLP-1 secretion in the acute setting.
Metformin has been demonstrated to reduce the active reabsorption of bile acids in the terminal ileum via inhibition of the apical sodium-dependent bile acid transporter (ASBT) (7, 8, 13) . The subsequent modifications of bile acid-mediated activation of the nuclear farnesoid X receptor (FXR) and the cell surface Takeda G proteincoupled receptor (TGR5) might influence GLP-1 secretion from L cells. In line with this, Trabelsi et al. (14) reported that bile acid-mediated FXR activation in L cells inhibited intracellular glycolytic pathways with a subsequent reduction in GLP-1 production and secretion, whereas bile acid-mediated activation of TGR5 has been demonstrated to induce GLP-1 secretion via increased adenosine triphosphate/adenosine 5 0 -diphosphate ratio and cyclic adenosine 5 0 -monophosphate levels in the L cells (15) . An effect of TGR5 activation on GLP-1 secretion is supported by studies reporting increased plasma GLP-1 concentrations as a result of rectal or colonic administration of bile acids in patients with type 2 diabetes (16, 17) . Furthermore, the specific ASBT inhibitors GSK2330672 and 264W94 have been reported to cause marked reductions of plasma glucose levels in humans and increased GLP-1 concentrations in rodents, respectively (18, 19) .
In the current study, we extend our previous findings of GLP-1 secretion following single-dose metformin and/or cholecystokinin (CCK)-mediated gallbladder emptying in healthy young men (20) to patients with type 2 diabetes. Thus, we evaluated the isolated and combined effects of CCK-mediated gallbladder emptying and single-dose metformin on GLP-1 secretion and glucose metabolism in patients with type 2 diabetes.
Subjects and Methods

Study design
This study was a randomized, placebo-controlled, and double-blinded crossover trial with plasma GLP-1 excursion as the primary endpoint. Each of 15 participants was submitted to 4 experimental study days with administration of either singledose 1500 mg metformin or placebo in combination with intravenous infusion of CCK or saline. Thus, on experimental days, subjects received placebo + saline, metformin + saline, placebo + CCK, or metformin + CCK, respectively. The sequence of the 4 study days was randomized, and the experimental days were performed within a period of maximum 4 months and with at least 2 weeks between individual visits. Patients were instructed to pause ongoing single-drug glucoselowering treatment with metformin 7 days prior to each of the individual study days. Metformin treatment was resumed in the additional timespan between study days.
Study approval
This study was performed at Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, after approval from the Ethics Committee of the Capital Region of Denmark (registration no. H-15007280). The study was registered at the Danish Data Protection Agency (registration no. 2012-58-0004) and ClinicalTrials.gov (ID: NCT02497313). Oral and written informed consent was received from participants prior to inclusion in the study, which was conducted in accordance with the principles of the Declaration of Helsinki (seventh revision, 2013).
Experimental procedures
At each of the 4 study days, patients arrived at the laboratory after an overnight total fast and remained fasted for nutrients throughout the 4-hour investigation period. Two cannulas were inserted in the cubital veins bilaterally for collection of blood samples and administration of saline or CCK. The forearm chosen for blood sampling was placed under a heating pad (42°C) for arterialization of blood throughout the experiment. Baseline blood samples were drawn after a 10-minute rest and heat up of the hand.
At time 0 minutes, 1500 mg study drug (metformin/placebo) was administered alongside a 100 ml watery mixture of 1.500 mg acetaminophen for indirect assessment of gastric emptying. Subsequently, a 60-minute intravenous 40 ml infusion of saline or CCK (0. 4 
Peptides and materials
Metformin 500 mg (Orifarm, Odense, Denmark) and matching placebo tablets (Pharmacy of the Capital Region, Herlev, Denmark) were applied as study drugs. A total of 1500 mg Pinex® (acetaminophen) effervescent tablets (Actavis, Dublin, Ireland) was used for indirect assessment of gastric emptying. Synthetic sulfated CCK-8 (Bachem, Weil am Rhein, Germany) was formulated for infusion (Pharmacy of the Capital Region, Herlev, Denmark) using 2% human albumin (Statens Serum Institut, Copenhagen, Denmark) and sterilized water with subsequent sterile filtration and testing for microbiological contamination before experimental use.
Calculations and statistical analysis
Results are reported as median values with interquartile range, unless otherwise stated. Basal values of glucose and hormones are reported as the mean of three consecutive measurements (230, 215, and 0 minutes) prior to administration of study drug and start of infusion. The trapezoidal rule was applied for calculation of area under curve values and presented as baseline-subtracted area under curve (bsAUC), unless otherwise stated. Insulin secretion rate values were calculated by deconvolution of measured C-peptide concentrations and application of population-based parameters for C-peptide kinetics. GraphPad Prism version 7.0 (GraphPad Software, La Jolla, CA) was used for statistical analyses. One-way repeated measures analysis of variance with Fisher's least significant difference post hoc test was used to test for variations and differences with a two-tailed P value ,0.05 considered statistically significant. Log transformation of non-Gaussian distributed data was performed prior to statistical analysis. No adjustments for multiple comparisons have been performed for analyses of the metabolic parameters outlined above.
Results
Subject characteristics
This study included metformin-treated male (n = 12) and postmenopausal female patients (n = 3) with type 2 . The reported fasting plasma glucose and HbA1c concentrations were measured during ongoing metformin treatment at a screening visit prior to inclusion in the study. Key exclusion criteria included any liver or gastrointestinal disease, hypo-or hyperthyroidism, or nephropathy. Ongoing metformin treatment comprised immediate release formulation in all included patients, and the majority of these were treated with 1000 mg twice daily.
Glucose excursions
No significant differences in baseline plasma glucose concentrations were evident between the 4 experimental study days (Table 1) . On all 4 study days, these fasting plasma glucose concentrations were significantly increased (P , 0.05) compared with the on-treatment baseline concentration reported above, which confirms an effect of metformin washout. Metformin single dose 1500 mg, both with (P = 0.02) and without (P = 0.02) concomitant CCK-induced gallbladder emptying, elicited reduced plasma glucose excursions as measured by bsAUC compared with placebo (Table 1 ; Fig. 1 ). No isolated effects of CCK infusion on plasma glucose concentrations were observed (Table 1) .
GLP-1
We observed no significant differences in baseline plasma GLP-1 concentrations between the study days ( Table 1) . A significant increase in bsAUC for GLP-1 was evident following CCK infusion (P = 0.02), whereas isolated administration of metformin did not meet statistical significance in terms of GLP-1 bsAUC compared with the day with placebo and saline (P = 0.17) (Table 1; Fig. 1) . Interestingly, the combination of metformin and CCK significantly enhanced GLP-1 secretion with significantly higher bsAUC for GLP-1 compared with the days with metformin (P , 0.01) and CCK alone (P = 0.02) ( Table 1 ; Fig. 1 ).
Glucagon, C-peptide, and insulin secretion rate
Baseline plasma glucagon and serum C-peptide concentrations did not differ between the 4 experimental Table 1 for information on differences between the 4 days. study days (Table 1) . No metformin or CCK-mediated effects on plasma glucagon excursions were evident (Table 1 ; Fig. 2 ). Furthermore, we observed no metformin or CCK-mediated effects on C-peptide excursions or insulin secretion rates (Table 1 ; Fig. 2 ).
CCK and gallbladder dynamics
No differences in baseline gallbladder volumes were observed between the experimental study days ( Table 2) . Infusion of CCK increased the bsAUC for this hormone compared with saline, whereas no effect of metformin on CCK excursions was observed ( Table 2) . Along these lines, significant gallbladder contraction in terms of reduced minimum volume and bsAUC was evident on the 2 days with CCK infusion compared with saline days (Table 2 ). Figure 3 provides an overview on plasma CCK concentrations and gallbladder dynamics.
Gastric emptying
Infusion of CCK caused a delay in gastric emptying. Thus, significantly reduced maximum concentrations and a trend toward increased time to maximum plasma concentration of acetaminophen were observed after CCK compared with saline (Table 2 ; Fig. 4) . No effect of metformin on gastric emptying compared with placebo was evident.
Resting energy expenditure
We observed no significant differences in baseline values for resting energy expenditure between the study days. In addition, no differences in d values (time 0 minutes to time 60 minutes) were evident with estimates (kJ/24 hours) of 49 [28; 180] 
Discussion
In this study, we show that CCK-induced gallbladder emptying in patients with type 2 diabetes elicits a significant increase in plasma GLP-1 excursion that can be further enhanced by concomitant administration of singledose metformin, whereas metformin alone had a minor effect on the increase in plasma GLP-1 concentrations.
The marked and statistically significant increase in plasma GLP-1 concentrations after CCK infusion and concomitant metformin compared with the 3 days with Figure 2 . The graphs on top show serum C-peptide concentrations and bsAUC 240 min scatter plots (bars represent median and interquartile range) for serum C-peptide on the 4 different study days. The graphs below illustrate plasma glucagon excursions in relation to the various interventions (median with interquartile range) and bsAUC 240 min scatter plots (bars represent median and interquartile range) for plasma glucagon. Met, metformin; Pla, placebo. See Table 1 for calculations on differences between the 4 days. doi: 10.1210/jc.2017-01091 https://academic.oup.com/jcemplacebo, metformin, and CCK, respectively, is in line with the findings by Rohde et al. (20) in subjects with normal glucose tolerance. Furthermore, a range of studies has reported increased GLP-1 excursions following continuous metformin treatment in both healthy subjects and patients with type 2 diabetes, submitted to standardized meal test or oral glucose load (8) (9) (10) (11) 21) . In contrast to the study by Rohde et al. (20) , in which single-dose metformin was reported to induce GLP-1 secretion in healthy subjects, no significant isolated effect of metformin on GLP-1 concentrations was observed in the current study, including patients with type 2 diabetes. This apparent discrepancy might be due to inadequate metformin washout or a result of the established difference in bile acid pool composition between healthy subjects and patients with type 2 diabetes (22) . The latter holds potential implications for FXR-and TGR5-mediated GLP-1 secretion (14, 15) . In addition, genetic variations in metformin-transporting proteins could be speculated to have influenced the GLP-1 secretory effect of isolated metformin in the current study (23) . However, all included patients had acceptable glycemic control with metformin as single-drug glucose-lowering therapy, which points to sufficient absorption capacity in these patients. Our findings are consistent with previous studies by Mannucci et al. and Lindsay et al. (11, 24) that found no acute metformin-mediated induction of GLP-1 secretion in patients with type 2 diabetes following an oral glucose load and in the fasting state, respectively. The GLP-1 excursions observed in the current study did reveal a tendency to a rise after metformin (particularly toward the end of the experimental days), thereby suggesting a latent onset metformin-induced GLP-1 secretion in line with an adenosine monophosphateactivated protein kinase-mediated GLP-1 secretory effect of metformin previously proposed by Duca et al. (6) . Studies have demonstrated no changes in fasting plasma GLP-1 concentrations following dipeptidyl peptidase-4 (DPP-4) inhibition or gastric bypass surgery (25, 26) . In addition, DPP-4 inhibition was reported to elicit a 5 to 10 pmol/L increase in meal-induced plasma concentrations of intact GLP-1 (25), whereas a 10-fold increase in postprandial total GLP-1 concentrations was observed following gastric bypass surgery in patients with type 2 diabetes (26). However, a comparison with the GLP-1 increments observed in the current study should be performed with caution due to the fasting setting and measurement of only total GLP-1.
The glucose-lowering effect of continuous treatment with metformin is well established (27) , whereas the acute metformin-mediated glucometabolic effects in patients with type 2 diabetes have been examined to a much lesser extent. We observed single-dose administration of 1500 mg metformin to elicit statistically significant placebo-corrected reductions in plasma glucose excursions, both alone and in combination with CCK-induced gallbladder emptying, whereas no glucose-lowering effect of isolated CCK infusion was observed. We observed no concomitant metformin-mediated effects on C-peptide or glucagon excursions, which points to no GLP-1-mediated a,b rmANOVA P = 0.42 P , 0.0001 effects of metformin on fasting plasma glucose in the acute setting. In studies by Lindsay et al. and Sambol et al. (24, 28) , there was no acute glucose-lowering effect of metformin in the fasting state in patients with type 2 diabetes, which contrasts our results. However, the first study applied a lower metformin dose of 1000 mg and did not examine the effects of metformin during concomitant intestinal appearance of bile acids (24) . In addition, in the study by Sambol et al. (28) , an immediate improvement of postprandial plasma glucose excursions was observed, which is in accordance with the glucose-lowering effect of combined metformin and CCK observed in our study during conditions resembling postprandial bile acid circulation. The mechanisms behind metformin-mediated potentiation of GLP-1 secretion from enteroendocrine L cells remain to be clarified (29) . A metformin-mediated induction of the L cell secretory response rather than a suppression of DPP-4 activity is supported by the increase in total GLP-1 (intact + metabolites) observed in the current study (21, 29, 30) . A recent study has reported metformin to reduce the rate of glucose absorption along the proximal parts of the small intestine, which was suggested to hold implications for GLP-1 secretion due to an intensified glucose-mediated stimulation of the large population of L cells in the more distal part of the ileum (31) . However, the relevance of this proposed mechanism seems negligible in the current study design with no intake of nutrients. A range of in vitro studies has examined the direct effects of metformin on GLP-1 secretion and reported contradicting results (6, 29, 32, 33) . Interestingly, in a study of GLUTag cells, Kappe et al. (33) reported no direct GLP-1 secretory effect of metformin, but found a metformin-mediated sensitizing effect on L cells with increased nutrient-induced GLP-1 secretion following metformin treatment. This L cell-sensitizing effect of metformin appears to be in accordance with the metformin-mediated potentiation of bile acid-induced GLP-1 secretion observed in our study. In a recent review, Bahne et al. (34) suggested the metformin-induced potentiation of GLP-1 secretion to involve modulation of enterohepatic bile acid circulation. Along these lines, a metformin-induced inhibition of ASBT could be speculated to elicit a beneficial balance between postabsorptive activation of the nuclear FXR and the basolaterally located TGR5 in terms of GLP-1 secretory effects, which Table 2 for calculations on differences between the 4 days.
would require a concomitant, sustained stimulation of TGR5 and a decrease in FXR activation (14, 15, 35) . The simultaneous peak GLP-1 concentrations at time 60 minutes on the 2 days with CCK alone and concomitant metformin administration would be in accordance with such a mechanism. A sustained increase in GLP-1 concentrations was evident after the combination of CCK and metformin compared with placebo [also seen in the study by Rohde et al. (20) ], thereby raising the possibility of a bile acid-induced stimulation of L cells in the more distal parts of the gastrointestinal tract as an explanation for the metformin-mediated potentiation of GLP-1 secretion, which has previously been suggested in relation to specific ASBT inhibition (19) . Nevertheless, the mechanisms behind the metformin-mediated potentiation of bile acidinduced GLP-1 secretion remain speculative at this point.
We do not suspect that the CCK infusion has direct effects on GLP-1 secretion in the present setting with twofold peak CCK plasma concentrations compared with the normal postprandial rises (36) . Thus, a study by Hansen and Holst (37) demonstrated no induction of GLP-1 secretion in a perfused porcine ileum model following application of CCK in a concentration 10 to 50 times normal postprandial levels. The observed placebocorrected increase in bsAUC for plasma GLP-1 following CCK-induced gallbladder emptying is in agreement with previous studies investigating bile acid-mediated effects on GLP-1 secretion in patients with type 2 diabetes (16, 38) .
We observed no effects of either metformin administration or CCK infusion on resting energy expenditure, and the single-dose approach makes glucose-lowering effects caused by changes in bile acid or gut microbiota compositions implausible in the present setting. No clear associations were evident between the GLP-1-inducing effects and insulin secretion or plasma glucose levels, which might have been due to an impaired b cell responsiveness to GLP-1 in patients with type 2 diabetes (39). GLP-1-independent mechanisms involving direct hepatic effects and increased splanchnic glucose utilization might have contributed to the observed acute glucose-lowering impact of metformin (3, 5) . Nevertheless, the metformin-mediated potentiation of GLP-1 secretion might prove beneficial in a postprandial setting via potential delay of gastric emptying and satietyinducing effects.
The marked delaying effect on gastric emptying caused by increased plasma CCK concentrations on study days Table 2 for information on differences between the 4 days.
with CCK infusion is in agreement with previous studies (40) . However, Rohde et al. (20) applied a similar lead time between gastric tube administration of study drug and initiation of CCK infusion, with no significant CCKmediated impact on acetaminophen absorption (20) . Similar acetaminophen pharmacokinetics was expected in the present setting due to oral administration of a small volume watery mixture. We suspect no pharmacodynamic consequences of the observed effect on gastric emptying in the current setting due to similar bsAUC for acetaminophen on the 2 study days with metformin administration. Nonetheless, the observed differences in maximum acetaminophen concentration and time to maximum acetaminophen concentration on the 2 days including metformin might be speculated to have influenced metformin pharmacokinetics within the gastrointestinal tract.
In conclusion, we found single-dose administration of metformin to enhance bile acid-induced GLP-1 secretion in patients with type 2 diabetes, whereas no significant isolated effect of metformin on GLP-1 secretion was observed. The metformin-mediated reductions in plasma glucose excursions (with and without CCK) without concomitant changes in C-peptide and glucagon excursions point to no acute GLP-1-mediated effect of metformin on fasting plasma glucose. The underlying mechanisms of metformin-induced GLP-1 secretion remain speculative, but might involve metformin-mediated modulation of bile acid circulation with potential subsequent implications for bile acid receptor activation in the GLP-1-secreting L cells, as well as sensitization of these enteroendocrine cells by metformin.
